Immuno-oncology biotech Immune Design files for a $60 million IPO

Comment

Shutterstock photo

Immune Design, an early-stage biotech developing immunotherapy cancer treatments, filed on Monday with the SEC to raise up to $60 million in an initial public offering. The Seattle, WA-based company, which was founded in 2008 and booked $1.1 million in licensing and product sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol IMDZ. Immune Design initially filed confidentially on 4/24/2014. Jefferies & Co., and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com